跳至主要内容
临床试验/NCT05083559
NCT05083559已完成不适用

A Crossover Study to Assess the Efficacy of a Robust AP Closed Loop System vs MPC Closed Loop System

Oregon Health and Science University1 个研究点 分布在 1 个国家目标入组 15 人开始时间: 2021年12月8日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
15
试验地点
1
主要终点
Area Under the Curve (AUC) of Postprandial Glucose

研究概览

简要总结

An artificial pancreas (AP) is a control system for automatic insulin delivery. The investigators have implemented a missed meal bolus detection algorithm for use within an AP control system. The robust R-AP system used in this protocol has been designed to handle a variety of real-world scenarios that are critical to a high-risk patient population. The investigators will test how well the new algorithm handles missed or inaccurate meal announcements. This type of algorithm may significantly improve glucose control over the standard model predictive control (MPC) closed-loop algorithm without these new algorithm features for patients with type 1 diabetes.

详细描述

Participants will undergo two visits at Oregon Health and Science University (OHSU) that will evaluate missed meal bolus detection. Participants will arrive at approximately 7am for all visits, be monitored through the afternoon and discharged before dinner. During each of these intervention visits, participants will wear an Omnipod to deliver insulin and a Dexcom G6 Continuous Glucose Monitoring System (CGM) to measure glucose. The closed loop system will receive activity data through a Polar M600 watch worn by the participant. The studies will test the ability of the system to adapt to a missed meal bolus. Participants will eat self selected meals at 10 am and 2pm, both meals with a missed bolus, and these meals will be repeated across both study arms. For one missed meal bolus study, glucose will be controlled using the Robust R-AP closed-loop mode. During the other missed meal bolus study, glucose will be controlled using the MPC closed-loop mode. Participants will complete frequent glucose and ketone checks for safety.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Diagnosis of type 1 diabetes mellitus for at least 1 year.
  • •Male or female participants 18 to 65 years of age.
  • •Current use of an insulin pump for at least 3 months with stable insulin pump settings for >2 weeks.
  • •HbA1c ≤ 10.5% at screening.
  • •Total daily insulin requirement is less than 139 units/day.
  • •Willingness to follow all study procedures, including attending all clinic visits.
  • •Willingness to sign informed consent and HIPAA documents.

排除标准

  • •Female of childbearing potential who is pregnant or intending to become pregnant or breast-feeding, or is not using adequate contraceptive methods. Acceptable contraception includes birth control pill / patch / vaginal ring, Depo-Provera, Norplant, an intra-uterine device (IUD), the double barrier method (the woman uses a diaphragm and spermicide and the man uses a condom), or abstinence.
  • •Any cardiovascular disease, defined as a clinically significant EKG abnormality at the time of screening or any history of: stroke, heart failure, myocardial infarction, angina pectoris, or coronary arterial bypass graft or angioplasty. Diagnosis of 2nd or 3rd degree heart block or any non-physiological arrhythmia judged by the investigator to be exclusionary.
  • •Renal insufficiency (GFR < 60 ml/min, using the Modification of Diet in Renal Disease (MDRD) equation as reported by the OHSU laboratory).
  • •Liver failure, cirrhosis, or any other liver disease that compromises liver function as determined by the investigator.
  • •Hematocrit of less than 36% for men, less than 32% for women.
  • •History of severe hypoglycemia during the past 12 months prior to screening visit or hypoglycemia unawareness as judged by the investigator. Participants will complete a hypoglycemia awareness questionnaire. Participants will be excluded for four or more R responses.
  • •History of diabetes ketoacidosis during the prior 6 months prior to screening visit, as diagnosed on hospital admission or as judged by the investigator.
  • •Adrenal insufficiency.
  • •Any active infection.
  • •Known or suspected abuse of alcohol, narcotics, or illicit drugs.
  • •Seizure disorder.
  • •Active foot ulceration.
  • •Severe peripheral arterial disease characterized by ischemic rest pain or severe claudication.
  • •Major surgical operation within 30 days prior to screening.
  • •Use of an investigational drug within 30 days prior to screening.
  • •Chronic usage of any immunosuppressive medication (such as cyclosporine, azathioprine, sirolimus, or tacrolimus).
  • •Bleeding disorder, treatment with warfarin, or platelet count below 50,
  • •Allergy to aspart insulin.
  • •Current administration of oral or parenteral corticosteroids.
  • •Any life threatening disease, including malignant neoplasms and medical history of malignant neoplasms within the past 5 years prior to screening (except basal and squamous cell skin cancer).
  • •Beta blockers or non-dihydropyridine calcium channel blockers.
  • •Current use of any medication intended to lower glucose other than insulin (ex. use of liraglutide).
  • •Gastroparesis
  • •Any clinically significant disease or disorder which in the opinion of the Investigator may jeopardize the participant's safety or compliance with the protocol.

研究组 & 干预措施

MPC AP system

Experimental

Participants will use the MPC AP system for automated insulin delivery for a 9 hour study visit.

干预措施: MPC AP algorithm (Device)

Robust R-AP system

Experimental

Participants will use the Robust R-AP system for automated insulin delivery for a 9 hour study visit.

干预措施: Robust R-AP algorithm (Device)

结局指标

主要结局

Area Under the Curve (AUC) of Postprandial Glucose

时间窗: 4 hour period following the first meal

Incremental AUC of postprandial glucose in the 4 hours following the start of first meal. AUC (mg/dL\*hr) will be calculated using a trapezoidal method, which sums all CGM values taken every 5 minutes in the 4 hour period following the meal above the starting glucose. This yields a maximum of 48 data points for the calculation.

Percent of Time With Sensed Glucose Between 70-180 mg/dl

时间窗: 4 hour period following the first meal

Assess the percent of time that the Dexcom G6 reported sensor glucose values between 70-180 mg/dl using Dexcom sensor for the four hour period following the first meal.

次要结局

  • Number of Carbohydrate Treatments(4 hour period following the first meal)
  • Number of Provider-administered Insulin Injections(4 hour period following the first meal)
  • Percent of Time With Sensed Glucose <54 mg/dl(4 hour period following the first meal)
  • Percent of Time With Sensed Glucose >250 mg/dl(4 hour period following the first meal)
  • Mean Amount of Insulin Delivered Per Day (in Units)(4 hour period following the first meal)
  • Mean Sensed Glucose(4 hour period following the first meal)
  • Percent of Time With Sensed Glucose <70 mg/dl(4 hour period following the first meal)
  • Percent of Time With Sensed Glucose >180 mg/dl(4 hour period following the first meal)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Jessica Castle

Principal Investigator

Oregon Health and Science University

研究点 (1)

Loading locations...

相似试验